Evidence map›Paper›PMID 27325209›Full record

ReviewTrends in neurosciences2016

Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease?

Bryce A Mander, Joseph R Winer, William J Jagust, Matthew P Walker

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in neurosciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 259 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
259citing papers in PubMed, 8 pooled it
23.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

259 citing papers in PubMed, 8 syntheses or guidelines pooled it, 470 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Acoustic stimulation as a promising technique to enhance slow-wave sleep in Alzheimer's disease: results of a pilot study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2023
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Review
  20. Article

199 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Bryce A ManderSleep and Neuroimaging Laboratory University of California, Berkeley, CA 94720-1650, USA. Electronic address: bamander@berkeley.edu.
Joseph R WinerSleep and Neuroimaging Laboratory University of California, Berkeley, CA 94720-1650, USA.
William J JagustHelen Wills Neuroscience Institute, University of California, Berkeley, CA 94720-1650, USA; Molecular Biophysics and Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Matthew P WalkerSleep and Neuroimaging Laboratory University of California, Berkeley, CA 94720-1650, USA; Helen Wills Neuroscience Institute, University of California, Berkeley, CA 94720-1650, USA. Electronic address: mpwalker@berkeley.edu.
University of California, Berkeley · USLawrence Berkeley National Laboratory · US

Funding

Neural and Biochemical Mechanisms of Cognitive AgingR01AG034570 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI William J. Jagust · 2009 to 2026
$12.0M
Tau pathology, sleep disruption, and hippocampal memory decline in older adultsRF1AG054106 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI WALKER, MATTHEW P · 2017 to 2018
$4.7M
Sleep Loss, Human Memory and Brain Plasticity across the LifespanR01AG031164 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI WALKER, MATTHEW P · 2008 to 2019
$4.7M
A sleep electroencephalography biomarker predicting Alzheimer's disease pathologyRF1AG054019 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI WALKER, MATTHEW P · 2016 to 2016
$4.1M
Aging, sleep, and beta-amyloid pathology and their impact on memoryF32AG039170 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI MANDER, BRYCE A. · 2010 to 2013
$160k
NIA NIH HHS F32 AG039170NIA NIH HHS R01 AG031164NIA NIH HHS R01 AG034570NIA NIH HHS RF1 AG054019NIA NIH HHS RF1 AG054106
6 · The paper itself

Abstract

Sleep disruption appears to be a core component of Alzheimer's disease (AD) and its pathophysiology. Signature abnormalities of sleep emerge before clinical onset of AD. Moreover, insufficient sleep facilitates accumulation of amyloid-β (Aβ), potentially triggering earlier cognitive decline and conversion to AD. Building on such findings, this review has four goals: evaluating (i) associations and plausible mechanisms linking non-rapid-eye-movement (NREM) sleep disruption, Aβ, and AD; (ii) a role for NREM sleep disruption as a novel factor linking cortical Aβ to impaired hippocampus-dependent memory consolidation; (iii) the potential diagnostic utility of NREM sleep disruption as a new biomarker of AD; and (iv) the possibility of sleep as a new treatment target in aging, affording preventative and therapeutic benefits.

Indexed as

AgingAlzheimer DiseaseAnimalsHumansSleepagingAlzheimer's diseaseamyloid-βcognitive declinesleep

Identifiers

PMID27325209
PMCPMC4967375
OpenAlexW2440154114

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.